tiprankstipranks
Trending News
More News >
Instil Bio (TIL)
NASDAQ:TIL
US Market

Instil Bio (TIL) AI Stock Analysis

Compare
347 Followers

Top Page

TI

Instil Bio

(NASDAQ:TIL)

29Underperform
Instil Bio's overall stock score reflects substantial financial and operational challenges. The lack of revenue and ongoing losses are significant concerns, compounded by negative cash flows and the risk of equity dilution. Technical analysis indicates bearish momentum, and valuation metrics underscore the company's struggle with profitability. Without clear strategic improvements, the stock remains a high-risk investment.
Positive Factors
Financial Stability
Instil Bio is sufficiently capitalized with $115.1MM to fund operations through upcoming key milestones.
Milestone Payment
Instil Bio is expected to submit an IND for SYN-2510 in the U.S., potentially triggering a $10MM milestone payment.
Negative Factors
Clinical Development Delays
For the second time, Instil has pushed out the initiation of the U.S. trial evaluating AXN-2510 in combo with chemo as a treatment for 1L NSCLC to YE25.
Competitive Pressure
Instil appears to be losing ground to multiple new assets that are expected to submit INDs by YE25.

Instil Bio (TIL) vs. S&P 500 (SPY)

Instil Bio Business Overview & Revenue Model

Company DescriptionInstil Bio is a biotechnology company focused on developing innovative cancer therapies. Specializing in tumor-infiltrating lymphocyte (TIL) technology, Instil Bio is dedicated to advancing cell therapy treatments that harness the power of the immune system to combat solid tumors. The company operates in the biopharmaceutical sector, aiming to provide novel therapeutic options for patients with unmet medical needs in oncology.
How the Company Makes MoneyInstil Bio generates revenue primarily through the development and commercialization of its TIL-based therapies. The company may enter into strategic partnerships and collaborations with other biotech firms, research institutions, or pharmaceutical companies to co-develop and commercialize therapies, which can include upfront payments, milestone payments, and royalties based on sales. Additionally, as its products move through clinical trials and, if successful, receive regulatory approval, revenue can be generated from the sale of these therapies to healthcare providers and institutions treating cancer patients. Other potential revenue streams could include licensing its technology to other companies in the biotechnology and pharmaceutical sectors.

Instil Bio Financial Statement Overview

Summary
Instil Bio is facing significant financial challenges, characterized by no revenue generation, ongoing losses, and negative cash flows. While the balance sheet shows liquidity strength, the reliance on equity financing poses dilution risks. The company's financial health is precarious, requiring substantial strategic shifts to achieve sustainable operations.
Income Statement
10
Very Negative
Instil Bio has reported no revenue for several consecutive years, indicating significant challenges in monetizing its technology or products. The absence of revenue coupled with consistent and substantial net losses highlight severe profitability issues. Although there is a reduction in net loss from the prior year, the company still faces major financial hurdles.
Balance Sheet
30
Negative
The company maintains a reasonable cash position with cash and short-term investments of $113 million, providing some liquidity. However, the debt-to-equity ratio is low due to minimal debt, which is a positive. The equity ratio indicates a strong reliance on equity financing, suggesting potential dilution risks for investors. Overall, the balance sheet shows liquidity strength but significant equity erosion over time.
Cash Flow
25
Negative
Operating cash flow remains deeply negative, reflecting ongoing operational losses. There is a notable decrease in negative free cash flow from the previous year, indicating some improvement in cash management. However, consistent negative cash flow from operations poses a significant risk to financial sustainability without additional financing.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.00138.00K
Gross Profit
0.00-4.76M-5.99M-2.75M138.00K
EBIT
-73.54M-90.54M-226.46M-155.56M-33.64M
EBITDA
-62.53M-146.12M-217.38M-154.00M-33.39M
Net Income Common Stockholders
-74.14M-156.09M-223.18M-156.79M-37.74M
Balance SheetCash, Cash Equivalents and Short-Term Investments
113.31M150.36M260.92M454.10M241.71M
Total Assets
263.57M325.63M482.13M609.98M319.01M
Total Debt
1.02M86.05M79.90M0.000.00
Net Debt
-7.79M76.86M36.19M-37.59M-241.71M
Total Liabilities
94.13M99.80M118.52M54.78M358.61M
Stockholders Equity
169.44M225.83M363.61M555.20M-39.60M
Cash FlowFree Cash Flow
-55.70M-102.69M-264.75M-179.97M-80.43M
Operating Cash Flow
-55.70M-82.03M-180.16M-122.14M-29.62M
Investing Cash Flow
53.97M41.13M114.54M-474.40M-51.12M
Financing Cash Flow
1.75M8.08M71.89M393.16M313.05M

Instil Bio Technical Analysis

Technical Analysis Sentiment
Negative
Last Price11.72
Price Trends
50DMA
18.26
Negative
100DMA
20.28
Negative
200DMA
24.66
Negative
Market Momentum
MACD
-0.77
Positive
RSI
38.90
Neutral
STOCH
20.31
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TIL, the sentiment is Negative. The current price of 11.72 is below the 20-day moving average (MA) of 15.88, below the 50-day MA of 18.26, and below the 200-day MA of 24.66, indicating a bearish trend. The MACD of -0.77 indicates Positive momentum. The RSI at 38.90 is Neutral, neither overbought nor oversold. The STOCH value of 20.31 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TIL.

Instil Bio Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
51
Neutral
$5.35B3.41-40.83%2.89%18.11%2.60%
39
Underperform
$111.76M-31.94%30.76%
38
Underperform
$96.41M-44.03%86.65%
36
Underperform
$78.68M-95.69%23.55%
36
Underperform
$88.60M-80.74%
TITIL
29
Underperform
$81.59M-37.51%52.54%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TIL
Instil Bio
11.72
1.00
9.33%
NKTX
Nkarta
1.95
-5.54
-73.97%
TNYA
Tenaya Therapeutics
0.48
-4.20
-89.74%
ZURA
Zura Bio
1.39
-2.76
-66.51%
KYTX
Kyverna Therapeutics, Inc.
2.04
-14.57
-87.72%

Instil Bio Corporate Events

Business Operations and StrategyFinancial Disclosures
Instil Bio Reports 2024 Financial Results and Outlook
Neutral
Mar 4, 2025

Instil Bio reported its fourth quarter and full year 2024 financial results, highlighting a decrease in cash and marketable securities compared to the previous year. The company anticipates significant clinical developments in 2025, including data updates and trial initiations for its lead asset AXN-2510/IMM2510 in collaboration with ImmuneOnco, which could impact its operations and industry positioning.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.